FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target.
Although a standardized approach to radiotherapy has been used to treat breast cancer, regardless of subtype (e.g., luminal, basal), recent clinical data suggest that radiation response may vary significantly among subtypes. We hypothesized that this clinical variability may be due, in part, to differences in cellular radiation response. In this study, we utilized RNA samples for microarray analysis from two sources: 1. Paired pre- and postirradiation breast tumor tissue from 32 early-stage breast cancer patients treated in our unique preoperative radiation Phase I trial; and 2. Sixteen biologically diverse breast tumor cell lines exposed to 0 and 5 Gy irradiation. The transcriptome response to radiation exposure was derived by comparing gene expression in samples before and after irradiation. Genes with the highest coefficient of variation were selected for further evaluation and validated at the RNA and protein level. Gene editing and agonistic antibody treatment were performed to assess the impact of gene modulation on radiation response. Gene expression in our cohort of luminal breast cancer patients was distinctly different before and after irradiation. Further, two distinct patterns of gene expression were observed in our biologically diverse group of breast cancer cell lines pre- versus postirradiation. Cell lines that showed significant change after irradiation were largely luminal subtype, while gene expression in the basal and HER2+ cell lines was minimally impacted. The 100 genes with the most significant response to radiation in patients were identified and analyzed for differential patterns of expression in the radiation-responsive versus nonresponsive cell lines. Fourteen genes were identified as significant, including FAS, a member of the tumor necrosis factor receptor family known to play a critical role in programed cell death. Modulation of FAS in breast cancer cell lines altered radiation response phenotype and enhanced radiation sensitivity in radioresistant basal cell lines. Our findings suggest that cell-type-specific, radiation-induced FAS contributes to subtype-specific breast cancer radiation response and that activation of FAS pathways may be exploited for biologically tailored radiotherapy.
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Janet K
JK
Horton
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Sharareh
S
Siamakpour-Reihani
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Chen-Ting
CT
Lee
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Ying
Y
Zhou
b  Department of Bioinformatics at Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Wei
W
Chen
c  Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Joseph
J
Geradts
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Diane R
DR
Fels
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Peter
P
Hoang
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Kathleen A
KA
Ashcraft
c  Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Jeff
J
Groth
d  Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina.|e  Center for Genomic and Computational Biology, Duke University Medical Center, Durham, North Carolina.
Hsiu-Ni
HN
Kung
a  Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Mark W
MW
Dewhirst
d  Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina.|e  Center for Genomic and Computational Biology, Duke University Medical Center, Durham, North Carolina.
Jen-Tsan A
JT
Chi
D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D005260:Female; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D020411:Oligonucleotide Array Sequence Analysis; D010641:Phenotype; D021381:Protein Transport / Q000528:radiation effects; D011836:Radiation Tolerance / Q000235:genetics*; D015533:Transcriptional Activation / Q000528:radiation effects; D059467:Transcriptome / Q000528:radiation effects; D019014:fas Receptor / Q000235:genetics* / Q000378:metabolism
D014408:Biomarkers, Tumor; D019014:fas Receptor